Target intelligence / Profile preview

Enterovirus 71 viral capsid proteins (EV71 capsid proteins)

Target
EV71 capsid proteins
Molecular classification
Viral protein, Capsid protein, Structural protein
01

Overview

Enterovirus 71 (EV71) is a significant human pathogen within the Picornaviridae family, primarily known as a major causative agent of hand, foot, and mouth disease (HFMD) and severe neurological complications in young children (PubMed: 29434377). The viral capsid is an icosahedral shell composed of 60 protomers, each containing four structural proteins: VP1, VP2, VP3, and VP4, which serve to protect the viral RNA and facilitate host cell entry (UniProt: P03300). VP1 is the most surface-exposed protein and plays a critical role in binding to host receptors such as SCARB2 and PSGL-1 (PubMed: 22437571). Because these capsid proteins are essential for the initial stages of the viral life cycle, they are primary targets for antiviral drug development and vaccine design. Small-molecule inhibitors, known as capsid binders, typically lodge in a hydrophobic pocket in VP1 to prevent viral uncoating, while inactivated and recombinant vaccines utilize these proteins to elicit protective neutralizing antibodies (PubMed: 25108375, PubMed: 24581533).

Other names
EV-A71 capsid proteinsVP1VP2VP3VP4P1 precursor proteinEnterovirus A71 structural proteins
02

Mechanism of action

Capsid binders interact with a hydrophobic pocket (often referred to as the canyon) located within the VP1 protein; this interaction stabilizes the viral capsid and prevents the conformational changes required for viral uncoating and the subsequent release of the viral RNA genome into the host cell (PubMed: 25108375, PubMed: 22437571).

03

Biological functions

Viral attachmentViral entryViral uncoatingGenome packagingCapsid assemblyReceptor binding
04

Disease associations

Hand, foot, and mouth disease (HFMD)EncephalitisAseptic meningitisAcute flaccid paralysisInfection
05

Safety considerations

Rapid emergence of drug-resistant mutations within the VP1 hydrophobic pocket (PubMed: 22437571)Limited clinical efficacy of capsid binders when administered after the onset of severe neurological symptomsPotential for narrow spectrum of activity across different enterovirus genotypes
06

Interacting drugs

Pleconaril

4 more in the full profile.

07

Biomarkers

EV71 VP1-specific IgM/IgG antibodiesViral RNA load (RT-PCR)VP1 sequence mutations (for drug resistance monitoring)

Beyond the preview

Go deeper on Enterovirus 71 viral capsid proteins (EV71 capsid proteins).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Enterovirus 71 viral capsid proteins (EV71 capsid proteins).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call